Buy - Price 13 on Sept. 30 by Sterne, Agee & Leach Given the attractive spreads between [mortgage-backed securities] yields and borrowing costs...we think NLY should be able to deliver a mid-teens [return on equity]...our 17 target is based on a 30% premium to current tangible book value of 1 times...The shares...yield 16.9%, versus the agency-mortgage real-estate investment trust peer-group averages of 18.8%. Market cap: $7.7 billion.

Outperform/Speculative - Price 30.77 on Sept. 30 by Morgan Keegan We're lowering estimates on this exploration-and-production company to reflect an adjusted price forecast of $85 oil and $7 natural gas...Enterprise value/[earnings before interest, taxes, depreciation and amortization] is 9 times; five-year estimated EPS growth rate, 10%. Market cap: $1.4 billion.

Hold - Price 37.99 on Sept. 30 by Jefferies & Co. Our 38 target for CSH is about 11 times our '09 [earnings-per-share] estimate of $3.41....We expect CSH's purchase of 100 Mexican pawn operations to fully offset lost income associated with closing CSH's Pennsylvania and Minnesota online payday-lending businesses. Market cap: $1 billion.

Market Outperform - Price 79.44 on Sept. 30 by Avondale Partners CHTT saw a 3% increase in revenues...in this difficult environment, which shows [health-product] brand resiliency. We're raising non-GAAP [fiscal-year] '08 and FY09 estimates to $4.23 and $4.90. Market cap: $1.5 billion.

In Line - Price 17.75 on Sept. 30 by Fox-Pitt Kelton Citi's acquisition of Wachovia banking operations provides a very compelling risk/reward equation...We assume $6.5 billion of annualized provision expense for future-loan production. This should translate to annualized net revenue of at least $17.1 billion. We estimate this deal will be 4% accretive to '09 EPS, excluding...merger costs. Market cap: $96.7 billion.

Outperform - Price 26.79 on Sept. 29 by Baird Associates Forest is a leader in the [central-nervous-system drug] market....and Lexapro exclusivity should now be secure through March '12. Forest has about $2.6 billion in cash and $800+ million of annual free cash flow...We look for FRX to [keep] expanding its product line; 41 target is 12.5 times our [calendar-year] '09 EPS estimate of $3.47, discounted back at 10%. Market cap: $8.2 billion.

Sell - Price 19 on Sept. 30 by Zacks Research Core 2Q08 results were two cents ahead of our expectations...[while trading] at a discount to the peer median (on a price/earnings basis), with more than two-thirds of the loan portfolio in residential real estate in the New York metropolitan area, and considering industry overhangs...we remain cautious...Six-month target, 16.25, equates to a negative 16.1% expected total return. Market cap: $10 billion.

Outperform/Speculative - Price 11.15 on Sept. 29 by Barrington Research Target: 25; raising our 2008E EPS to $3.34, from $3.22. We believe OSK is in the process of raising product prices to pass along raw-material inflation. Market cap: $940 million.